Compare Immunovant Inc. Common Stock (IMVT) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Invesco NASDAQ 100 ETF — how do they compare? Immunovant Inc. Common Stock trades at $30.47 (market cap $6.25B), while Invesco NASDAQ 100 ETF trades at $309.39 (market cap $113.40B). The key difference: Invesco NASDAQ 100 ETF is far larger — about 18.1× Immunovant Inc. Common Stock's market cap, and Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 1 Days and Invesco NASDAQ 100 ETF for 54 Days on average.
| IMVT | QQQM | |
|---|---|---|
Market Cap | $6.25B | $113.40B |
Volume | 1,755,411 | 2,866,236 |
Sector | Health | Broad Market / Factor |
52-Week High | $44.96 | $312.76 |
52-Week Low | $17.03 | $229.87 |
Typical Hold Time | 1 Days | 54 Days |
Enterprise Value | $5.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QQQM trades at $307.85, down 1.33% today, while maintaining a bullish technical outlook with strong moving average support. The Invesco NASDAQ 100 ETF continues to benefit from institutional accumulation, with QRG Capital Management increasing its position by 207.5% in Q2 2026. Technical indicators show the ETF trading near key resistance at $309, with support established at $305 and $303 levels. The fund's 0.15% expense ratio provides a cost advantage over similar NASDAQ-100 tracking products.
QQQM offers efficient exposure to NASDAQ-100 growth stocks with lower fees, though concentration in technology sectors presents volatility risks. Institutional buying signals confidence in the ETF's long-term prospects despite recent market fluctuations. Investors should monitor technology sector performance and interest rate sensitivity as key drivers of future returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
